CompletedPhase 3NCT02525523

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

Studying Pouchitis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Atlantic Pharmaceuticals Ltd
Principal Investigator: Chris Dunk
Atlantic Pharmaceuticals
Intervention: Alicaforsen(drug)
Enrollment: 138 target
Eligibility: 18 years · All sexes
Timeline: 2015 – 2018

Study locations (30)

Site Reference ID/Investigator# 1008, La Jolla, California, United States
Site Reference ID/Investigator # 1005, Los Angeles, California, United States
Site Reference ID/Investigator#1011, Stanford, California, United States
Site Reference ID/Investigator#1012, Atlanta, Georgia, United States
Site Reference ID/Investigator# 1010, Chicago, Illinois, United States
Site Reference ID/Investigator# 1001, Rochester, Minnesota, United States
Site Reference ID/Investigator# 1003, Great Neck, New York, United States
Site Reference ID/Investigator# 1006, New York, New York, United States
Site Reference ID/Investigator# 1009, New York, New York, United States
Site Reference ID/Investigator# 1004, Cleveland, Ohio, United States
Site Reference ID/Investigator# 1002, Oklahoma City, Oklahoma, United States
Site Reference ID/Investigator# 1007, Seattle, Washington, United States
Site Reference ID/Investigator# 0103, Brussels, Belgium
Site Reference ID/Investigator# 0102, Ghent, Belgium
Site Reference ID/Investigator# 0101, Leuven, Belgium
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02525523 on ClinicalTrials.gov

Other trials for Pouchitis

Additional recruiting or active studies for the same condition.

See all trials for Pouchitis →

← Back to all trials